Skip to main content
Français
Search form
Search
Follow the Fraser Institute:
Contact us
About us
Our experts
Donate
Home
Research
Aboriginal Policy
Aging, Retirement, and Pensions
Competitiveness
COVID-19
Economic Freedom
Education Policy
Energy
Environment
ESG - Environmental, Social and Governance
Federal Reform Series
Gov't Spending & Taxes
Health Care
Labour Policy
Monetary Policy and Banking
Municipal Policy
Natural Resources
Poverty and Inequality
Provincial Prosperity
Realities of Socialism
School Report Cards
Essential Scholars
Other Research Topics
More from the Fraser Institute
Education Programs
Western Canada BC, AB, SK, MB, NT, YT, NU
For Students
For Teachers
For Journalists
Central Canada ON, QC, NB, NS, PE, NL
Peter Munk Centre for Free Enterprise Education
For Students
For Teachers
For Journalists
Economic Freedom
School Rankings
Blog
Events
Founders' Award
Other Events
Podcast
Women, Economic Progress, and Markets
Fraser Forum
Donate
Who was Barbara Mitchell?
tarceva
tarceva
tarceva
November 7, 2013
2:00AM
Potential Impact of Delayed Access to Five Oncology Drugs in Canada
Dr. Nigel Rawson
Tags:
health care
,
drug approval process
,
oncology drugs
,
cancer survival
,
halaven
,
jevtana
,
tarceva
,
torisel
